Hotgen(SH:688068) Ge Long Hui A P P·2026-01-16 08:38Core Viewpoint - The company, 热景生物 (Hotgen Biotech), is expected to experience a significant decline in revenue and an increase in net losses for the fiscal year 2025 compared to the previous year [1] Financial Performance - The projected revenue for 2025 is estimated to be between 400 million yuan and 420 million yuan, representing a year-on-year decrease of 17.79% to 21.71% [1] - The expected net profit attributable to the parent company for 2025 is forecasted to be between -210 million yuan and -230 million yuan, indicating an increase in losses of 9.94% to 20.42% compared to the previous year [1] - The net profit attributable to the parent company, after deducting non-recurring gains and losses, is anticipated to be between -250 million yuan and -270 million yuan for 2025 [1]